REDMOND, Wash., July 16 /PRNewswire/ -- EndoGastric Solutions, the world leader in natural orifice surgery (NOS), announces that Dr. Kelvin Higa, professor of surgery at UCSF-Fresno and the President of the American Society for Metabolic and Bariatric Surgery, and Dr. John Hunter, Mackenzie Professor and Chairman of Surgery, a world-renowned foregut surgeon, and past President of Society of American Gastrointestinal Endoscopic Surgeons, have joined EndoGastric Solutions’ Scientific Advisory Board.
“A new generation of minimally invasive bariatric products are on the horizon that are designed for endoluminal surgery,” said Higa. “This is the vehicle that will lead us to improved results. With more $25 Billion spent annually on obesity, transoral products promise to expand the number of patients who can benefit from a surgical solution and, at the same time, reduce the cost and risk associated with traditional or laparoscopic surgery. EsophyX and StomaphyX are among the most innovative engineering I have seen and offer significant advances with incisionless surgery.”
“With a growing number of patients unhappy with daily PPI use, the need for a minimally invasive, natural orifice surgical product that achieves similar results to Nissen will revolutionize the way we treat GERD patients,” said Hunter. “The EsophyX platform looks like it will be able to achieve this and, as we iterate the device and procedure, we hope to improve upon EsophyX ELF’s already impressive results.”
About EndoGastric Solutions, Inc.
EndoGastric Solutions(TM) is a pioneer in natural orifice surgery for the treatment of gastrointestinal diseases, including GERD and obesity. EndoGastric Solutions’ mission is to utilize the most current wisdom in gastroenterology and surgery to develop new transoral procedures and products to address the largest unmet needs in gastrointestinal diseases. EndoGastric Solutions’ technologies involve modifying current open surgical and/or laparoscopic approaches by using transoral access instead of abdominal incisions. The company designs and manufactures single-use instruments that will enable these incisionless solutions, and focuses on clinically based products for use by gastroenterologists and surgeons.
StomaphyX is available in the United States. EsophyX is not available for sale or use in the United States. Both devices are CE marked and available in the European Union.
For more information about the European School of Laparoscopic Surgery, please visit: http://www.lap-surgery.com/html/ed_school.html
For more information about EndoGastric Solutions, Inc., EsophyX and StomaphyX please visit:
In the US: http://www.endogastricsolutions.com In the EU: http://www.egseurope.eu Other locations throughout the globe: http://www.egsglobal.net Contact Information: Press Contact: Jason Thompson Marketing Communications Manager 206-218-5982 jthompson@endogastricsolutions.com Investor Relations: Guy Seaton Chief Financial Officer 425-307-3200 gseaton@endogastricsolutions.com US Customer Contact: Larry K. Fulton Senior Director of U.S. Sales EndoGastric Solutions, Inc. lfulton@endogastricsolutions.com European Customer Contact: Joan McLoughlin Vice President, Education +32-487-175-933 jmcloughlin@endogastricsolutions.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
EndoGastric Solutions, Inc.
CONTACT: Press Contact, Jason Thompson, Marketing Communications Manager,+1-206-218-5982, or jthompson@endogastricsolutions.com, or InvestorRelations, Guy Seaton, Chief Financial Officer, +1-425-307-3200, orgseaton@endogastricsolutions.com, or US Customer Contact, Larry K. Fulton,Senior Director of U.S. Sales, lfulton@endogastricsolutions.com, orEuropean Customer Contact, Joan McLoughlin, Vice President, Education,+32-487-175-933, or jmcloughlin@endogastricsolutions.com, all ofEndoGastric Solutions, Inc.
